Interview with the Director, President and CEO: Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Dinesh V. Patel, Ph.D., is Director, President and CEO of Protagonist Therapeutics, Inc. Dr. Patel has served as a member of the board of directors and as the President and Chief Executive Officer of Protagonist since December 2008. He has 33 years of executive, entrepreneurial and scientific experience that span the pharmaceutical, biotechnology and biopharmaceutical industries. Prior to joining Protagonist Therapeutics, Dr. Patel served from 2006 to 2008 as the President and Chief Executive Officer of Arete Therapeutics, a privately held company focused on novel drugs for metabolic syndrome. Previously, he was the Chief Executive Officer and Co-Founder of Miikana Therapeutics, an oncology-based company, from 2003 until acquired by Entremed — later renamed CASI Pharmaceuticals — in 2005. Prior to Miikana, Dr. Patel was a founding member at Versicor — now Vicuron — where he held positions of increasing responsibility from 1996 to 2003. Vicuron has two marketed drugs, anidulafungin, or Eraxis, and dalbavancin, or Dalvance, and it was acquired by Pfizer in 2005 in a $1.9 billion cash transaction. From 1993 to 1996, Dr. Patel was a director of chemistry at the combinatorial chemistry company Affymax. Dr. Patel was a medicinal chemist at Bristol-Myers Squibb from 1985 to 1993. Dr. Patel received his Ph.D. in chemistry from Rutgers University, New Jersey and his B.S. in industrial chemistry from S. P. University, Vallabh Vidyanagar, India. Profile
Word count: 2,554
TWST: What is Protagonist Therapeutics?
Dr. Patel: First and foremost, we are a drug company that is focused exclusively on peptide